The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
Preclinical data suggest synergy between cisplatin and the ataxia telangiectasia and Rad3-related inhibitor elimusertib, leading to this phase Ib trial in advanced solid tumors evaluating feasibility. The results do not support further examination of the combination due to DLTs observed in the absence of robust efficacy.
Authors
- Mamta Parikh (ORCID: https://orcid.org/0000-0002-7300-7452)
- Anne M. Noonan (ORCID: https://orcid.org/0000-0001-8083-8492)
- Nataliya V. Uboha (ORCID: https://orcid.org/0000-0003-3449-1680)
- Jan H. Beumer (ORCID: https://orcid.org/0000-0002-8978-9401)
- Kari B. Wisinski (ORCID: https://orcid.org/0000-0003-3535-0652)
- Philippe Lucien Bedard (ORCID: https://orcid.org/0000-0002-6771-2999)
- Kit Tam (ORCID: https://orcid.org/0009-0001-5392-4739)
- Arjun Mittra (ORCID: https://orcid.org/0000-0001-9572-3495)
- Yuanquan Yang (ORCID: https://orcid.org/0000-0002-5209-9247)
- Alexey Valeryevich Danilov (ORCID: https://orcid.org/0000-0003-4461-0970)
- Primo N. Lara (ORCID: https://orcid.org/0000-0001-9512-0002)
- Ming Yin (ORCID: https://orcid.org/0000-0001-5743-4369)
- Edward M. Newman (ORCID: https://orcid.org/0000-0001-6988-5909)
- Paul Frankel (ORCID: https://orcid.org/0000-0003-2231-6121)
- Naoko Takebe (ORCID: https://orcid.org/0000-0002-5790-4954)
- Christopher Ruel (ORCID: https://orcid.org/0000-0002-7205-0803)
- Julianne L. Holleran (ORCID: https://orcid.org/0000-0002-3738-8200)
- Steven D. Gore (ORCID: https://orcid.org/0009-0007-2139-5653)
Institutions
- City Of Hope National Medical Center (US)
- University Health Network (CA)
- University of Wisconsin–Madison (US)
- Johns Hopkins University (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Princess Margaret Cancer Centre (CA)
- The Ohio State University Wexner Medical Center (US)
- University of Wisconsin Carbone Cancer Center (US)
- Ohio State University Hospital (US)
- City of Hope (US)
- UPMC Hillman Cancer Center (US)
- Comprehensive Blood & Cancer Center (US)
- National Cancer Institute (US)
- University of California Davis Medical Center (US)
- Tidelands Health (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UC Davis Comprehensive Cancer Center
- The Ohio State University (US)
- University of Baltimore (US)
- University of California, Davis (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0305
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Eisai
- Astellas Pharma
- Ipsen
- National Institutes of Health
- National Cancer Institute